Cancer diagnostics firm Foundation Medicine, a member of the Roche Group, has introduced its new liquid biopsy test for solid tumours for commercial use in the US.
The blood test, called FoundationOne Liquid, is a hybrid capture-based, sequencing in vitro diagnostic device designed to detect substitutions, insertion and deletion alterations (indels), copy number alterations (CNAs) and select gene rearrangements.
The device uses a blood sample to analyse 70 genes, including homologous recombination deficiency (HRD), that increase the growth of cancer and then reports the genomic biomarker for microsatellite instability (MSI).